Harmony Biosciences Holdings, Inc. (HRMY) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Plymouth Meeting, PA, United States. El CEO actual es Jeffrey Dayno.
HRMY tiene fecha de IPO 2020-08-19, 268 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $1.69B.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
